Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividen

Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertis

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's adv

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as in

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outper

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketi

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading a

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it wort

Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against riva

Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, acc

Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-mar

Futures on the Dow Jones Industrial Average (DJI) and Nasdaq-100 Index (NDX) are comfortably higher

Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival o

The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weigh

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Li

Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing ​the U.S.

Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its bloc

Novo Nordisk shares have rallied approximately 27% since my previous coverage, driven by acceleratin

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but toug

Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter result

Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter result

Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are a

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

Novo Nordisk ​will launch a more affordable authorised copy of its Ozempic diabetes drug in ‌South A

Novo Nordisk has made robust gains of 40% at the stock markets since April, supported by the success

The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipf

Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity dr

All three can be bought on the dip.

Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous tra

Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franch

A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Med

A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Med

The European Commission approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill, a once-daily oral semaglu

Novo Nordisk wins EU approval for Wegovy pill, the first oral GLP-1 for weight management, backed by

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by

Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weigh

Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation f

India's Sun Pharmaceutical Industries has received approval from South Africa's health regulator to

Novo Nordisk reports new phase 3 denecimig and concizumab data showing low bleeding rates and consis

NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic w

AdaptHealth disclosed a material cyberattack involving patient data and insurance billing passwords

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Medicare GLP-1 coverage starts Wednesday. Here’s what patients should know about cost, eligibility a

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

The Medicare GLP-1 Bridge program will be the first time eligible Medicare Part D patients will be a

White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide throug

Novo-Nordisk shares are trading higher by more than 6% on Monday as GLP‑1 support initiatives aimed

As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today